Palvella Therapeutics PVLA Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $1.07M+106% | $520K-17.2% | $628K-9.0% | $690K-8.2% | $752K+168% | ||
| $9.33M+31.1% | $7.12M+9.1% | $6.53M+27.5% | $5.12M+25.6% | $4.07M+60.2% | ||
| $5.52M+32.0% | $4.18M+14.6% | $3.65M-11.7% | $4.13M+8.8% | $3.8M+108% | ||
| $14.86M+31.4% | $11.3M+11.1% | $10.18M+10.0% | $9.25M+17.5% | $7.87M+80.3% | ||
| -$14.86M-31.4% | -$11.3M-11.1% | -$10.18M-10.0% | -$9.25M-17.5% | -$7.87M-80.3% | ||
| -$32K— | —— | $34K-93.9% | $561K+150% | $224K+22,500% | ||
| -$15.77M-24.0% | -$12.71M-12.1% | -$11.35M-19.8% | -$9.47M-15.7% | -$8.19M-107% | ||
| $0— | $0— | $0— | $0— | $0— | ||
| -$15.77M-24.0% | -$12.71M-12.1% | -$11.35M-19.8% | -$9.47M-15.7% | -$8.19M-107% | ||
| -$1.20-11.1% | -$1.08-4.9% | -$1.03-19.8% | -$0.86-16.2% | -$0.74— | ||
| -$14.86M-31.4% | -$11.3M-11.1% | -$10.18M-10.0% | -$9.25M-17.5% | -$7.87M-80.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Palvella Therapeutics's revenue?
- Palvella Therapeutics (PVLA) generated $40.9M in revenue over the trailing twelve months, up 142.9% year over year.
- Is Palvella Therapeutics profitable?
- Palvella Therapeutics is not currently profitable: it reported a net loss of $49.3M over the trailing twelve months, a 71.7% net margin.
- What is Palvella Therapeutics's earnings per share?
- Palvella Therapeutics's diluted EPS over the trailing twelve months is $-4.17.
- Where does Palvella Therapeutics's income statement data come from?
- Every line is extracted from Palvella Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
